Therapeutic Workshop Details
CNS: Advances in Neuropsychiatry - Anxiety, Depression, Psychoses; New Solutions to Complex Disorders
Thursday, October 11, 2007
8:15 AM
Sea Cliff
Neuropsychiatric disorders are among the most common illnesses treated by physicians. Despite dramatic advances in our understanding of brain disorders and how to treat illnesses such as depression, bipolar disease and anxiety disorders, there is still much uncharted territory to explore and there remains a clear unmet need for new therapies. This workshop will highlight some of the recent advances in the clinical development of pharmacological treaments of neuropsychiatric illnesses, elucidating some of the biological mechanisms responsible for these disorders.
Moderators
- William Ho; Vice President, Senior Research Analyst/Biotechnology, Banc of America Securities LLC
Panelists
- Stephen I. Bandak, MB, BS, MRCP; Chief Medical Officer, Synosia Therapeutics
- Uli Hacksell, PhD; Chief Executive Officer, ACADIA Pharmaceuticals Inc.
- Michael G. Kauffman, MD, PhD; Chief Executive Officer, EPIX Pharmaceuticals, Inc.
- Mark Varney, PhD; Chief Operating Officer and Chief Scientific Officer, Cortex Pharmaceuticals, Inc.
Who's Who
William Ho is a vice president and senior research analyst in the Equity Research Department at Banc of America Securities LLC, where he covers the Biotechnology Industry. Ho joined the Company from Piper Jaffray & Co. where he was a research analyst covering Biotechnology & Tools. Before that, he was a senior financial analyst in the Financial Planning & Operational Analysis division of CuraGen Corporation, a biopharmaceutical company focused on developing applications to treat cancer, inflammatory diseases and diabetes. Earlier, he was an associate in the health care investment banking group at SG Cowen. Ho received a master of business administration degree from the University of Notre Dame and a bachelor of science degree in biochemistry, with honors, from McMaster University in Canada.